Weekly Recap: Galleri benefit, low false positives and Q beat, shares up
GRAIL Inc (NASDAQ:GRAL) gained after FDA staff backed its Galleri test for multi-cancer detection with strong performance and low false positives, the company beat Q results (loss $2.56/sh, revenue $44.69M) and saw Mizuho lift its price target from $65 to $100.Previous Week RecapThis is an AI-gener…